HealthEquity (HQY)
Market Price (2/21/2026): $78.91 | Market Cap: $6.8 BilSector: Health Care | Industry: Managed Health Care
HealthEquity (HQY)
Market Price (2/21/2026): $78.91Market Cap: $6.8 BilSector: Health CareIndustry: Managed Health Care
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 23% | Weak multi-year price returns2Y Excs Rtn is -41%, 3Y Excs Rtn is -43% | Expensive valuation multiplesP/EPrice/Earnings or Price/(Net Income) is 35x |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 32%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 28% | Key risksHQY key risks include [1] the high sensitivity of its custodial revenue to interest rate declines and [2] regulatory or healthcare policy changes that could undermine the market for its core HSA products. | |
| Attractive yieldFCF Yield is 5.3% | ||
| Low stock price volatilityVol 12M is 42% | ||
| Megatrend and thematic driversMegatrends include Fintech & Digital Payments. Themes include Digital Payments, Online Banking & Lending, and Wealth Management Technology. |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 23% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 32%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 28% |
| Attractive yieldFCF Yield is 5.3% |
| Low stock price volatilityVol 12M is 42% |
| Megatrend and thematic driversMegatrends include Fintech & Digital Payments. Themes include Digital Payments, Online Banking & Lending, and Wealth Management Technology. |
| Weak multi-year price returns2Y Excs Rtn is -41%, 3Y Excs Rtn is -43% |
| Expensive valuation multiplesP/EPrice/Earnings or Price/(Net Income) is 35x |
| Key risksHQY key risks include [1] the high sensitivity of its custodial revenue to interest rate declines and [2] regulatory or healthcare policy changes that could undermine the market for its core HSA products. |
Qualitative Assessment
AI Analysis | Feedback
1. Lower-than-expected Fiscal Year 2027 Outlook. On January 12, 2026, HealthEquity announced an initial fiscal year 2027 revenue outlook ranging between $1.38 billion and $1.41 billion. This guidance was perceived by the market as modest or lower than prior expectations, contributing to a significant single-day stock decline of over 10% following the announcement.
2. Analyst Downgrade. On January 9, 2026, Goldman Sachs downgraded HealthEquity's stock from a "Hold" rating to a "Strong Sell," setting a new price target of $89.00. This substantial downgrade from a prominent investment firm likely eroded investor confidence and contributed to downward pressure on the stock.
Show more
Stock Movement Drivers
Fundamental Drivers
The -16.6% change in HQY stock from 10/31/2025 to 2/20/2026 was primarily driven by a -37.0% change in the company's P/E Multiple.| (LTM values as of) | 10312025 | 2202026 | Change |
|---|---|---|---|
| Stock Price ($) | 94.58 | 78.89 | -16.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,269 | 1,291 | 1.7% |
| Net Income Margin (%) | 11.5% | 14.9% | 29.3% |
| P/E Multiple | 56.1 | 35.4 | -37.0% |
| Shares Outstanding (Mil) | 87 | 86 | 0.6% |
| Cumulative Contribution | -16.6% |
Market Drivers
10/31/2025 to 2/20/2026| Return | Correlation | |
|---|---|---|
| HQY | -16.6% | |
| Market (SPY) | 1.1% | 36.4% |
| Sector (XLV) | 8.7% | 38.5% |
Fundamental Drivers
The -18.7% change in HQY stock from 7/31/2025 to 2/20/2026 was primarily driven by a -48.7% change in the company's P/E Multiple.| (LTM values as of) | 7312025 | 2202026 | Change |
|---|---|---|---|
| Stock Price ($) | 97.00 | 78.89 | -18.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,243 | 1,291 | 3.8% |
| Net Income Margin (%) | 9.8% | 14.9% | 51.7% |
| P/E Multiple | 69.0 | 35.4 | -48.7% |
| Shares Outstanding (Mil) | 87 | 86 | 0.8% |
| Cumulative Contribution | -18.7% |
Market Drivers
7/31/2025 to 2/20/2026| Return | Correlation | |
|---|---|---|
| HQY | -18.7% | |
| Market (SPY) | 9.4% | 35.8% |
| Sector (XLV) | 20.8% | 16.0% |
Fundamental Drivers
The -28.6% change in HQY stock from 1/31/2025 to 2/20/2026 was primarily driven by a -64.5% change in the company's P/E Multiple.| (LTM values as of) | 1312025 | 2202026 | Change |
|---|---|---|---|
| Stock Price ($) | 110.42 | 78.89 | -28.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,150 | 1,291 | 12.2% |
| Net Income Margin (%) | 8.4% | 14.9% | 76.8% |
| P/E Multiple | 99.6 | 35.4 | -64.5% |
| Shares Outstanding (Mil) | 87 | 86 | 1.4% |
| Cumulative Contribution | -28.6% |
Market Drivers
1/31/2025 to 2/20/2026| Return | Correlation | |
|---|---|---|
| HQY | -28.6% | |
| Market (SPY) | 15.6% | 46.6% |
| Sector (XLV) | 8.2% | 29.4% |
Fundamental Drivers
The 29.7% change in HQY stock from 1/31/2023 to 2/20/2026 was primarily driven by a 55.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312023 | 2202026 | Change |
|---|---|---|---|
| Stock Price ($) | 60.85 | 78.89 | 29.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 831 | 1,291 | 55.3% |
| P/S Multiple | 6.2 | 5.3 | -15.1% |
| Shares Outstanding (Mil) | 85 | 86 | -1.7% |
| Cumulative Contribution | 29.7% |
Market Drivers
1/31/2023 to 2/20/2026| Return | Correlation | |
|---|---|---|
| HQY | 29.7% | |
| Market (SPY) | 75.9% | 36.5% |
| Sector (XLV) | 23.1% | 20.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| HQY Return | -37% | 39% | 8% | 45% | -5% | -14% | 13% |
| Peers Return | 13% | -1% | 15% | 18% | -20% | -8% | 13% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 0% | 83% |
Monthly Win Rates [3] | |||||||
| HQY Win Rate | 42% | 58% | 42% | 67% | 42% | 0% | |
| Peers Win Rate | 53% | 48% | 57% | 65% | 45% | 30% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| HQY Max Drawdown | -43% | 0% | -17% | -0% | -20% | -20% | |
| Peers Max Drawdown | -15% | -16% | -5% | -5% | -32% | -11% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: WEX, VOYA, ADP, PAYX, FISV. See HQY Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/20/2026 (YTD)
How Low Can It Go
| Event | HQY | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -56.6% | -25.4% |
| % Gain to Breakeven | 130.3% | 34.1% |
| Time to Breakeven | 1,052 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -53.8% | -33.9% |
| % Gain to Breakeven | 116.4% | 51.3% |
| Time to Breakeven | 314 days | 148 days |
| 2018 Correction | ||
| % Loss | -48.2% | -19.8% |
| % Gain to Breakeven | 93.2% | 24.7% |
| Time to Breakeven | 1,866 days | 120 days |
Compare to WEX, VOYA, ADP, PAYX, FISV
In The Past
HealthEquity's stock fell -56.6% during the 2022 Inflation Shock from a high on 1/26/2021. A -56.6% loss requires a 130.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About HealthEquity (HQY)
AI Analysis | Feedback
Here are 1-3 brief analogies for HealthEquity (HQY):
- A Fidelity or Vanguard for Health Savings Accounts (HSAs).
- An ADP or Paychex for administering employee healthcare spending accounts.
- A Blue Cross Blue Shield for managing your healthcare money, rather than your health insurance.
AI Analysis | Feedback
- Health Savings Accounts (HSAs): Administration of tax-advantaged savings accounts for qualified medical expenses, integrated with high-deductible health plans.
- Flexible Spending Accounts (FSAs): Management of employer-sponsored, pre-tax accounts for healthcare and dependent care expenses.
- Health Reimbursement Arrangements (HRAs): Administration of employer-funded health benefit plans used to reimburse employees for medical costs.
- Commuter Benefits: Provision of pre-tax accounts for qualified transit and parking expenses, helping employees save on commuting costs.
- COBRA Administration: Comprehensive services for employers to manage the regulatory and administrative requirements of COBRA benefits.
- Well-Being & Lifestyle Accounts: Administration of customizable employer-funded accounts supporting employee wellness, lifestyle, and supplemental benefits.
AI Analysis | Feedback
HealthEquity (symbol: HQY) primarily sells its services to other companies (B2B) rather than directly to individuals.
The company provides Health Savings Accounts (HSAs) and other consumer-directed benefits (such as FSAs, HRAs, COBRA, and commuter benefits) through partnerships with various organizations.
Due to the nature of their business and confidentiality agreements, HealthEquity does not publicly disclose the names of specific major customer companies. However, their customer base primarily consists of the following categories of organizations:
- Employers: HealthEquity partners with a wide range of employers, from small businesses to large corporations, to offer health savings and spending accounts to their employees as part of their benefits packages.
- Health Plans (Insurance Carriers): The company collaborates with numerous health insurance carriers to integrate its solutions with their health plans, providing a comprehensive offering to the health plan's members.
AI Analysis | Feedback
| Supplier Company Name | Symbol |
|---|---|
| Charles Schwab & Co., Inc. | SCHW |
| Wells Fargo & Company | WFC |
| Wintrust Financial Corporation | WTFC |
AI Analysis | Feedback
Scott Cutler, President and Chief Executive Officer
Scott Cutler will become President and CEO of HealthEquity effective January 6, 2025. He previously served as Chief Executive Officer of StockX LLC since June 2019. Before StockX, Mr. Cutler was the Senior Vice President, Americas at eBay Inc. from August 2017 to March 2019, and President of StubHub, Inc. from April 2015 to August 2017. He also held the role of Executive Vice President at NYSE Euronext, Inc. from April 2006 to March 2015. Prior to joining NYSE Euronext, Mr. Cutler worked as a technology investment banker and corporate securities lawyer.
James Lucania, Executive Vice President and Chief Financial Officer
James Lucania serves as the Executive Vice President and Chief Financial Officer of HealthEquity, a position he assumed after the company's fiscal second-quarter 10-Q filing in September 2023. Before joining HealthEquity, Mr. Lucania was the Chief Financial Officer of Ascensus Holdings since 2016. His previous experience includes serving as Chief Financial Officer at CheckPoint Systems. Mr. Lucania also held various positions at Miller Buckfire & Co. and Levine Leichtman Capital Partners, a private equity firm.
Stephen D. Neeleman, MD, Founder and Vice Chairman
Dr. Stephen Neeleman is the Founder and Vice Chairman of HealthEquity. He founded HealthEquity in 2002, with a vision to reintroduce consumerism to healthcare and help people obtain quality health insurance. He served as President and Chief Executive Officer of HealthEquity from November 2002 through January 2014, and has been Vice Chairman since February 2014. In addition to his leadership at HealthEquity, Dr. Neeleman is a board-certified general and trauma surgeon. Before his medical training, he worked as the General Airport Manager for Morris Air, which was later acquired by Southwest Airlines.
Jon Kessler, Former President and Chief Executive Officer
Jon Kessler served as President and Chief Executive Officer of HealthEquity, a role he is retiring from effective January 6, 2025, after more than 15 years with the company. He joined HealthEquity in 2009. Mr. Kessler founded WageWorks, a provider of tax-advantaged programs for consumer-directed health, commuter, and other employee spending account benefits. He served as Chairman and CEO of WageWorks from 2000 to 2007. WageWorks was acquired by HealthEquity in 2019. Previously, Mr. Kessler was a senior economist in Washington, DC, specializing in employee benefits and environmental taxation during the Clinton and Bush (Sr.) administrations, and a benefits taxation specialist at Arthur Andersen, LLP. He also served as a Director of Redwood Equity Partners, Inc.
Del Ladd, Executive Vice President, General Counsel and Secretary
Del Ladd serves as the Executive Vice President, General Counsel and Secretary of HealthEquity, Inc., leading the company's Legal Department. He joined HealthEquity in 2016. Prior to his tenure at HealthEquity, Mr. Ladd worked at Willkie Farr & Gallagher LLP in New York, where he gained significant experience in corporate governance, securities, and mergers and acquisitions.
AI Analysis | Feedback
The key risks to HealthEquity's business are primarily centered around its revenue streams and the regulatory environment in which it operates.
- Interest Rate Sensitivity: A substantial portion of HealthEquity's revenue, specifically custodial revenue, is highly dependent on prevailing interest rates. A decline in interest rates could significantly slow the growth of or even reduce this revenue stream, as the company earns interest on Health Savings Account (HSA) cash assets deposited with its partners.
- Regulatory and Healthcare Policy Changes: HealthEquity's business model is built around tax-advantaged HSAs and other consumer-directed benefits. Changes in healthcare policy, legislation, or regulations, such as proposals for "Medicare for All" or shifts in HSA eligibility and contribution limits, could disrupt the market for these products and adversely affect the company's operations and profitability.
- Cybersecurity and Data Security Risks: As a major custodian of sensitive financial and protected health information, HealthEquity faces ongoing risks from cyber threats and data breaches. Such incidents could lead to significant reputational damage, a loss of customer trust, and substantial financial liabilities due to remediation expenses, legal costs, and regulatory fines.
AI Analysis | Feedback
Increased competition from large, integrated financial services firms, particularly Fidelity Investments, which offers a highly competitive Health Savings Account (HSA) product with low fees and robust investment options. Fidelity's strategy targets the investment component of HSAs, directly challenging HealthEquity's asset-based fee model and potentially drawing away high-balance, investment-savvy account holders. This is analogous to how a strong, established player with a different business model can leverage its existing infrastructure and expertise to disrupt specialized market incumbents.
AI Analysis | Feedback
HealthEquity (HQY) operates in the U.S. market, primarily focusing on Health Savings Accounts (HSAs) and other consumer-directed benefits (CDBs).
Here are the addressable market sizes for their main products and services:
- Health Savings Accounts (HSAs): The U.S. HSA market was estimated at approximately $146.6 billion in assets across 39.3 million accounts in 2024. This market is projected to grow to $199.1 billion in assets, held in over 45 million accounts, by the end of 2027. HealthEquity itself estimates the total number of HSAs could reach 50 million with $300 billion in assets by 2030.
- Flexible Spending Accounts (FSAs): In the U.S., an estimated 32.6 million FSAs were in force in 2022. The market for FSA solutions is anticipated to experience growth from 2024 to 2032. In 2020, approximately $30.7 billion was saved in FSAs in the U.S.
- Health Reimbursement Arrangements (HRAs): For the U.S. market, it is estimated that between 500,000 and one million lives are covered by Qualified Small Employer Health Reimbursement Arrangements (QSEHRAs) or Individual Coverage Health Reimbursement Arrangements (ICHRAs) in 2025. ICHRA adoption among large employers increased by 34% from 2024 to 2025 in the U.S.
- COBRA Administration: null
- Retirement Savings & Custodial Services: HealthEquity's offerings, particularly HSAs, contribute to retirement savings. The total U.S. retirement assets amounted to $45.8 trillion as of June 30, 2025. The U.S. custody, asset, and securities services market, which includes custodial services, was valued at $42.5 billion in 2024 and is projected to reach $45.7 billion in 2025.
AI Analysis | Feedback
HealthEquity (HQY) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market trends:
- Growth in HSA Members and Total Accounts: The company continues to expand its base of Health Savings Account (HSA) members and total accounts. In the third quarter of fiscal year 2025, HealthEquity reported 9.5 million HSAs and 16.5 million total accounts, and in the second quarter of fiscal year 2026, these numbers grew to 10.0 million HSAs and 17.1 million total accounts, respectively. This growth is fueled by new enterprise client wins and an expanded network partner footprint.
- Increase in HSA Assets and Custodial Yields: Growth in HSA assets under management directly boosts custodial revenue. HealthEquity benefits from higher interest rates, which enhance custodial yields. Management anticipates an average yield on HSA cash of approximately 3.5% for fiscal year 2026.
- Legislative Expansion of HSAs: Recent legislative changes are expected to significantly broaden the HSA market. These changes include allowing direct primary care arrangements and the use of low-cost telehealth services before deductibles are met. Additionally, starting January 1, 2026, all individual bronze and catastrophic plans will be permitted to be coupled with HSAs, potentially expanding the market to an additional 3-4 million American families. HealthEquity plans further investments in sales and marketing to capitalize on this "bronze-plan HSA expansion."
- AI-Driven Services and Technology Modernization: HealthEquity is investing in artificial intelligence (AI)-driven automation and a secure mobile experience to improve member satisfaction, reduce service costs, and decrease fraud rates. The company has successfully migrated its V5 platform to a fully cloud-based system, leading to 92% faster response times, increased platform stability, and an 80% reduction in delays. These technological advancements are aimed at enhancing efficiency and attracting more users.
- Strategic Acquisitions: HealthEquity's growth strategy includes pursuing further portfolio acquisitions to strengthen its proprietary health accounts platform and ecosystem. An example of this strategy is the anticipated acquisition of the BenefitWallet HSA portfolio, which was expected to be completed in the second quarter of fiscal year 2025.
AI Analysis | Feedback
Share Repurchases
- HealthEquity announced a $300 million stock repurchase program in September 2024.
- The company repurchased 1.4 million shares for $122.2 million during fiscal year 2025 (ended January 31, 2025).
- As of October 31, 2024, $240.0 million remained authorized for common stock repurchases under the company's program.
Share Issuance
- In July 2020, HealthEquity announced a public offering of 4,600,000 shares of common stock at $56.00 per share, with expected gross proceeds of $257,600,000.
- The number of outstanding shares increased from 76.00 million in 2020 to 86.66 million in 2024, reflecting an average annual increase of 3.03% over the past five years.
Outbound Investments
- HealthEquity completed the acquisition of Conduent's BenefitWallet HSA portfolio in fiscal year 2025.
- This acquisition involved the transfer of approximately 665,000 customer accounts and $2.7 billion in HSA assets, with a total purchase price of approximately $425 million.
- The first tranche of the BenefitWallet transfer occurred on March 7, 2024, involving 266,000 HSAs and $1.1 billion of HSA assets, for which HealthEquity paid $163.9 million.
Capital Expenditures
- Annual capital expenditures were $46.074 million in 2024, $119.127 million in 2023, and $137.081 million in 2022.
- Capital investments are focused on the company's proprietary platform and its connectivity within the health benefits ecosystem, leveraging cloud, data science, and API technology.
- Ongoing investments are also directed towards AI-driven automation and enhancing the secure mobile experience to improve member satisfaction and reduce service and fraud costs.
Latest Trefis Analyses
Trade Ideas
Select ideas related to HQY.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 01302026 | VEEV | Veeva Systems | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -14.6% | -14.6% | -15.7% |
| 01232026 | PAYX | Paychex | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | -11.5% | -11.5% | -13.3% |
| 01162026 | BIIB | Biogen | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 19.5% | 19.5% | 0.0% |
| 01162026 | BMRN | BioMarin Pharmaceutical | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 9.7% | 9.7% | 0.0% |
| 01162026 | DOCS | Doximity | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -39.4% | -39.4% | -40.1% |
| 12312021 | HQY | HealthEquity | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 30.4% | 39.3% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 85.07 |
| Mkt Cap | 20.0 |
| Rev LTM | 6,969 |
| Op Inc LTM | 2,237 |
| FCF LTM | 1,186 |
| FCF 3Y Avg | 1,255 |
| CFO LTM | 1,339 |
| CFO 3Y Avg | 1,346 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.9% |
| Rev Chg 3Y Avg | 7.5% |
| Rev Chg Q | 6.7% |
| QoQ Delta Rev Chg LTM | 1.6% |
| Op Mgn LTM | 26.3% |
| Op Mgn 3Y Avg | 25.9% |
| QoQ Delta Op Mgn LTM | -0.0% |
| CFO/Rev LTM | 26.2% |
| CFO/Rev 3Y Avg | 25.9% |
| FCF/Rev LTM | 20.8% |
| FCF/Rev 3Y Avg | 18.4% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 20.0 |
| P/S | 3.1 |
| P/EBIT | 11.2 |
| P/E | 19.2 |
| P/CFO | 15.6 |
| Total Yield | 8.6% |
| Dividend Yield | 1.2% |
| FCF Yield 3Y Avg | 5.2% |
| D/E | 0.3 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -6.6% |
| 3M Rtn | -6.8% |
| 6M Rtn | -20.9% |
| 12M Rtn | -29.6% |
| 3Y Rtn | -4.0% |
| 1M Excs Rtn | -7.1% |
| 3M Excs Rtn | -11.1% |
| 6M Excs Rtn | -28.6% |
| 12M Excs Rtn | -42.8% |
| 3Y Excs Rtn | -72.0% |
Comparison Analyses
Price Behavior
| Market Price | $78.89 | |
| Market Cap ($ Bil) | 6.8 | |
| First Trading Date | 07/31/2014 | |
| Distance from 52W High | -30.2% | |
| 50 Days | 200 Days | |
| DMA Price | $87.35 | $94.26 |
| DMA Trend | indeterminate | down |
| Distance from DMA | -9.7% | -16.3% |
| 3M | 1YR | |
| Volatility | 37.3% | 42.2% |
| Downside Capture | 138.70 | 93.65 |
| Upside Capture | -42.30 | 45.38 |
| Correlation (SPY) | 31.7% | 46.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.22 | 0.34 | 0.90 | 0.88 | 0.98 | 0.90 |
| Up Beta | 5.09 | 4.57 | 3.61 | 2.43 | 1.10 | 1.02 |
| Down Beta | 0.85 | 0.89 | 1.12 | 1.09 | 1.30 | 1.14 |
| Up Capture | -194% | -159% | -25% | 13% | 30% | 39% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 11 | 17 | 29 | 62 | 121 | 384 |
| Down Capture | -115% | 4% | 34% | 46% | 85% | 88% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 9 | 23 | 30 | 61 | 126 | 361 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HQY | |
|---|---|---|---|---|
| HQY | -31.1% | 42.3% | -0.77 | - |
| Sector ETF (XLV) | 8.6% | 17.3% | 0.32 | 29.8% |
| Equity (SPY) | 13.5% | 19.4% | 0.53 | 46.9% |
| Gold (GLD) | 74.5% | 25.6% | 2.15 | -10.5% |
| Commodities (DBC) | 7.2% | 16.9% | 0.25 | 14.3% |
| Real Estate (VNQ) | 7.1% | 16.7% | 0.24 | 30.2% |
| Bitcoin (BTCUSD) | -30.6% | 44.9% | -0.68 | 13.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HQY | |
|---|---|---|---|---|
| HQY | -1.6% | 39.7% | 0.08 | - |
| Sector ETF (XLV) | 7.6% | 14.5% | 0.34 | 19.7% |
| Equity (SPY) | 13.4% | 17.0% | 0.62 | 29.7% |
| Gold (GLD) | 22.6% | 17.1% | 1.08 | -11.2% |
| Commodities (DBC) | 10.9% | 19.0% | 0.46 | 10.6% |
| Real Estate (VNQ) | 5.0% | 18.8% | 0.17 | 12.9% |
| Bitcoin (BTCUSD) | 7.2% | 57.1% | 0.35 | 8.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HQY | |
|---|---|---|---|---|
| HQY | 16.3% | 44.6% | 0.50 | - |
| Sector ETF (XLV) | 11.3% | 16.5% | 0.57 | 38.5% |
| Equity (SPY) | 16.1% | 17.9% | 0.77 | 44.2% |
| Gold (GLD) | 14.8% | 15.6% | 0.79 | -10.9% |
| Commodities (DBC) | 8.6% | 17.6% | 0.40 | 18.1% |
| Real Estate (VNQ) | 7.0% | 20.7% | 0.30 | 30.4% |
| Bitcoin (BTCUSD) | 67.8% | 66.7% | 1.07 | 8.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 12/3/2025 | -3.0% | -3.0% | -3.2% |
| 9/2/2025 | 7.5% | 4.7% | 2.1% |
| 6/3/2025 | 9.0% | 3.3% | -1.9% |
| 2/18/2025 | 0.5% | -5.1% | -25.5% |
| 12/9/2024 | -5.6% | -7.8% | -0.7% |
| 9/3/2024 | 5.1% | -5.0% | 0.6% |
| 6/3/2024 | 2.7% | 7.0% | 2.9% |
| 2/21/2024 | 2.7% | 3.7% | 2.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 17 | 12 | 11 |
| # Negative | 7 | 12 | 13 |
| Median Positive | 3.7% | 3.8% | 2.9% |
| Median Negative | -5.6% | -5.8% | -7.2% |
| Max Positive | 11.6% | 10.3% | 14.7% |
| Max Negative | -24.6% | -27.4% | -48.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 10/31/2025 | 12/03/2025 | 10-Q |
| 07/31/2025 | 09/02/2025 | 10-Q |
| 04/30/2025 | 06/03/2025 | 10-Q |
| 01/31/2025 | 03/18/2025 | 10-K |
| 10/31/2024 | 12/09/2024 | 10-Q |
| 07/31/2024 | 09/03/2024 | 10-Q |
| 04/30/2024 | 06/03/2024 | 10-Q |
| 01/31/2024 | 03/22/2024 | 10-K |
| 10/31/2023 | 12/05/2023 | 10-Q |
| 07/31/2023 | 09/05/2023 | 10-Q |
| 04/30/2023 | 06/07/2023 | 10-Q |
| 01/31/2023 | 03/30/2023 | 10-K |
| 10/31/2022 | 12/08/2022 | 10-Q |
| 07/31/2022 | 09/08/2022 | 10-Q |
| 04/30/2022 | 06/08/2022 | 10-Q |
| 01/31/2022 | 03/31/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ladd, Delano | EVP, General Counsel | Direct | Sell | 12232025 | 94.72 | 1,500 | 142,080 | 7,007,291 | Form |
| 2 | Rosner, Elimelech | EVP, CHIEF TECHNOLOGY OFFICER | Direct | Sell | 12192025 | 95.45 | 10,959 | 1,046,090 | 4,366,298 | Form |
| 3 | Wellborn, Gayle Furgurson | Direct | Sell | 12162025 | 98.03 | 4,339 | 425,331 | 1,934,329 | Form | |
| 4 | Ladd, Delano | EVP, General Counsel | Direct | Sell | 11242025 | 104.56 | 1,500 | 156,840 | 7,892,084 | Form |
| 5 | Ladd, Delano | EVP, General Counsel | Direct | Sell | 10222025 | 92.07 | 1,500 | 138,105 | 7,087,457 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.